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Aspirin and P2Y12 inhibition attenuate
platelet-induced ovarian cancer cell invasion
Niamh M. Cooke1,2†, Cathy D. Spillane2,3,4†, Orla Sheils2,3, John O’Leary2,3,4 and Dermot Kenny1,2*
Abstract
Background: Platelet-cancer cell interactions play a key role in successful haematogenous metastasis. Disseminated
malignancy is the leading cause of death among ovarian cancer patients. It is unknown why different ovarian
cancers have different metastatic phenotypes. To investigate if platelet-cancer cell interactions play a role, we
characterized the response of ovarian cancer cell lines to platelets both functionally and at a molecular level.
Methods: Cell lines 59 M and SK-OV-3 were used as in vitro model systems of metastatic ovarian cancer. Platelet
cloaking of each cell line was quantified by flow cytometry. Matrigel invasion chamber assays were used to assess
the invasive capacity of the cell lines. The induction of an EMT was assessed by morphology analysis and by gene
expression analysis of a panel of 11 EMT markers using TaqMan RT-PCR.
Results: SK-OV-3 cells adhered to and activated more platelets than 59 M cells (p = 0.0333). Platelets significantly
promoted the ability of only SK-OV-3 cells to invade (p ≤ 0.0001). Morphology and transcritpome analysis
indicated that platelets induce an epithelial-to-mesenchymal transition phenotype in both cells lines, with a
more exaggerated response in SK-OV-3 cells. Next, we investigated if antiplatelet agents could abrogate the
platelet-induced aggressive phenotype in SK-OV-3 cells. Both aspirin (p ≤ 0.05) and 2-methylthioadenosine
5′-monophosphate triethylammonium salt hydrate (P2Y12 inhibitor; p ≤ 0.01) significantly decreased their
invasion capacity, and effectively reverted invasion to levels comparable to SK-OV-3 cells alone.
Conclusion: While there is increasing evidence for the cancer-protective effect of aspirin, this study suggests
P2Y12 inhibition may also play a role. Understanding these complex interactions between platelets and cancer
cells could ultimately allow the establishment of therapies tailored to inhibiting metastasis, thus significantly
reducing cancer morbidity.
Background
A growing body of evidence suggests that platelets have a
key role in successful haematogenous metastasis. Following
initial contact, the formation of tumour cell-induced plate-
let aggregates (TCIPA) facilitate immune evasion [1, 2],
provide angiogenic and growth factors [3, 4], and also pro-
mote microvascular arrest of at distant sites [5–7]. Experi-
mental blockade or deletion of platelet receptors interferes
with the TCIPA process, resulting in significantly decreased
metastasis [8, 9]. Additionally, similar results are observed
upon induction of thrombocytopenia in mice, an effect re-
versed by transfusion of platelet rich plasma [10, 11].
The ability of circulating tumour cells (CTCs) to sus-
tain the epithelial-mesenchymal transition (EMT) is es-
sential for cancer progression [12]. Many growth factors
and cytokines secreted from both stromal cells and
blood components contribute to this process, including
epidermal growth factor, insulin-like growth factor, and
hepatocyte growth factor as well as matrix metallopro-
teinases and urokinase plasminogen activator [13, 14].
Platelets also provide key instructive signals that affect
tumour cell invasiveness and metastatic potential. Using
mouse cells lines and models, Labelle et al. have demon-
strated that platelet-derived transforming growth factor
β (TGF-β) along with direct platelet-tumour cell contact
can induce EMT in tumour cells in vitro, and also en-
hance their extravasation and seeding in vivo [15]. More-
over, a recent study demonstrated a direct proliferative
effect of platelets on ovarian cancer cells mediated via
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TGF-β and partially dependent on platelet signalling
through cyclooxygenase-1 (COX-1) [16].
Ovarian cancer has the highest mortality rate of all
gynaecological malignancies and is the fifth leading
cause of all cancer-related deaths in women [17]. About
200,000 cases of ovarian cancer occur worldwide each
year. Over 70 % of ovarian cancer patients present with
advanced stage III and IV disease, which is associated
with a poor prognosis and high mortality rate [18]. Re-
cent studies have demonstrated that ovarian cancer
patients have an abundance of CTCs in their blood [19,
20]. Moreover these studies have identified ovarian can-
cer cells at distant sites, including the liver, spleen and
bone aspirates [21–23]. The biological mechanism for
hematogenous dissemination of ovarian cancer remains
poorly understood.
We have described a potent dynamic interaction be-
tween platelets and ovarian cancer cells in vitro, which
results in pro-survival and pro-angiogenic signalling in
the cancer cells [24]. In this current study, we sought
to further our understanding of this relationship by
characterising the interactions between platelets and
ovarian cancer cells. We investigated the effect of plate-
let adhesion to two ovarian cancer cell lines, and how
this communication can mediate platelet activation and
alter ovarian cancer cell EMT expression profile, morph-
ology and invasive behaviour. Since the antiplatelet agent
aspirin is associated with a reduce risk of death and dis-
tant metastasis in cancer patients [25–27] including
those with ovarian cancer [28], we investigated the
effect of aspirin and the antiplatelet P2Y12 blocker, 2-
methylthioadenosine 5′-monophosphate triethylammo-
nium salt hydrate (2MeSAMP), on the platelet cancer
cell interaction.
Methods
Ethics statement
Blood collection was approved by the Royal College of
Surgeons in Ireland ethics committee. Healthy female
donors who had not taken medications known to affect
platelet function for ≥10 days were recruited. Written in-
formed consent was obtained prior to phlebotomy.
Cell lines
Two metastatic ovarian cancer cell lines were employed
in this study, 59 M and SK-OV-3, both originating from
the ascites. 59 M cells [European collection of cell cul-
tures, Salisbury, UK] represent an ovarian epithelial
carcinoma of endometrioid type with clear cell compo-
nents. SK-OV-3 cells [American Tissue Culture Collec-
tion, Manassas, VA, USA] represent an ovarian epithelial
adenocarcinoma. 59 M cells were maintained in Dulbec-
co’s Modified Eagle Medium and SK-OV-3 cells in Mc-
Coy’s 5A media, each supplemented with 10 % fetal
bovine serum (FBS), 2 mM L-glutamine, 100 units/ml
penicillin, and 100 ug/ml streptomycin. Cells were cul-
tured in standard conditions in a humidified atmosphere
containing 5 % CO2 at 37 °C.
Platelet preparation
Whole blood was collected by venipuncture through a 19-
gauge butterfly needle. Platelet-rich plasma (PRP) was
prepared from 3.2 % trisodium citrated blood (10 % vol/
vol) centrifuged at 170 g for 10 min. For the preparation of
washed platelets, blood was collected into Acid-Citrate-
Dextrose (ACD: 38 mM citric acid, 75 mM sodium citrate,
124 mM D-glucose) as anticoagulant (15 % vol/vol) and
centrifuged at 170 g for 10 min. PRP was acidified to
pH 6.5 with ACD, 1 μM PGE1 was added and centrifuged
at 720 g for 10 min. The platelet pellet was resuspended
in JNL buffer [130 mM NaCl, 10 mM sodium citrate,
9 mM NaHCO3, 6 mM D-glucose, and 0.9 mM MgCl2,
0.81 mM KH2PO4, and 10 mM Tris, pH 7.4] and supple-
mented with 1.8 mM CaCl2.
Platelet adhesion assay
Platelet adhesion to ovarian cancer cells was measured
by flow cytometry, based on the detection of CD42b
(GPIbα) on the surface of cancer cells following co-
incubation. Washed suspensions of ovarian cancer cells
(1 × 106/ml) were incubated with PRP (1:1000 cancer
cell-platelet ratio) for 1 min under low shear on a rock-
ing table (12 oscillations per minute, opm). At this
ratio, no tumour cell-induced platelet aggregation is
observed, but there is efficient coating of tumour cells
by platelets with a degranulated phenotype [29]. Next,
samples were washed, fixed with 3.7 % paraformalde-
hyde, blocked with 1 % BSA and labelled with either
allophycocyanin (APC) mouse anti-human CD42b anti-
body or isotype control (Becton Dickinson). Samples
were analysed within 1 h by flow cytometry (Becton
Dickinson). Using a log forward scatter versus log side
scatter dot plot, a two dimensional analysis gate was
drawn around the cancer cell population, and a fluores-
cence histogram was obtained for 10,000 events for
each sample. Platelet aggregates and cancer cells duplets
were excluded using size based gating. Data was analysed
using BD FACS DIVA™ software. The percentage of plate-
let tumour cell adhesion was calculated as the percentage
of cells within the tumour cell gate positive for the platelet
specific marker CD42b relative to the isotype control.
Platelet activation assay
Platelet activation by ovarian cancer cells was mea-
sured by flow cytometry, based on the detection of P-
selectin (CD62P) on the surface of platelets following
co-incubation. P-selectin is stored internally in alpha-
granules of resting platelets and is translocated to the
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surface upon activation. Washed suspensions of cancer
cells (1 × 106/ml) were incubated with PRP (1:30 can-
cer cell-platelet ratio) for 15 min under low shear con-
ditions on a rocking table (12 opm). The reaction was
terminated with 1 ml of JNL buffer. Samples were
processed as described above and labelled with either
APC mouse anti-human P-selectin antibody or isotype
control (Becton Dickinson). Samples were analysed as
above, gating on the platelet population, and a fluores-
cence histogram was obtained for 10,000 events for
each sample. The percentage of tumour cell induced
platelet activation was calculated as the percentage of
P-selectin positive platelets relative to the isotype
control.
Platelet inhibitor preparation
Where indicated, cancer cell suspensions or washed plate-
let suspensions were treated with either 2MeSAMP, an
adenosine-based P2Y12 antagonist, or aspirin, a COX-1
antagonist. 2MeSAMP was dissolved in water, while as-
pirin was dissolved in 10 % dimethyl sulfoxide (DMSO).
Inhibitor incubation times were 15 min for 2MeSAMP
(50 μM) and 30 min for aspirin (20 μM) at 37 °C.
Platelet aggregation
Donors were verified as aspirin- and 2MeSAMP-
responders prior to inclusion in the study. Platelet aggre-
gation was assessed at 37 °C with continuous stirring
using a PAP-4/8 aggregometer (Bio-Data Corporation).
Aggregation was induced with 20 μM adenosine diphos-
phate (ADP) or 500 μg/ml arachidonic acid (Bio-Data
Corporation), and compared to platelets pre-treated with
2MeSAMP (50 μM) and ASA (20 μM). Platelet aggrega-
tion was expressed as the maximal percent change in
light transmittance from baseline, using platelet poor
plasma as reference. Responsiveness was defined as the
relative platelet inhibition induced by the addition of
either antiplatelet agent. Relative inhibition (RI) = [(pre-
treatment aggregation–post-treatment aggregation)/
(pre-treatment aggregation)] × 100 %. Responders were
defined as those with a RI of ≥70 %.
Cancer cell invasion assay
BioCoat® Matrigel® invasion chambers (8-μm pore size)
and corresponding control plates (BD Biosciences) were
used to examine the effect of platelets on cancer cell in-
vasion. Ovarian cancer cells were incubated with media
alone or washed platelets or drug treated washed plate-
lets (final cancer cell-platelet ratio 1:1000) for 24 h. After
incubation, suspensions were prepared in serum-free
medium (5 × 104 cells/ml) and allowed to invade
through Matrigel® and control chambers for 16 and 24 h
at 37 °C in 5 % CO2. Bottom wells contained 10 % FBS
as a chemoattractant. Invaded cells were fixed (10 %
formalin for 24 h) and fluorescently labelled (fluor-
oshield with DAPI). Filters were imaged using an epi-
fluorescence inverted microscope (Zeiss Axiovert-200)
and quantified with Image J (NIH). The number of cells
per 40× high power field (cells/hpf ) was determined in 3
random hpf, and the mean number of cells/hpf was cal-
culated for each membrane. All experiments were car-
ried out with a minimum of three wells per condition.
Data are expressed as percentage invasion through
Matrigel® chambers relative to the control.
RNA extraction
Ovarian cancer cells were incubated with media alone,
washed platelets or washed platelets pre-treated with an-
tiplatelet agent (cancer cell-platelet ratio 1:1000) for
24 h. After incubation, total RNA was extracted from
the samples using the miRVana Kit (Life Technologies),
according to the manufacturer’s protocol.
Real time PCR
The mRNA expression level of 11 EMT related genes
was profiled using a custom designed RT-PCR-based
TaqMan OpenArray® Panel (Life Technologies) following
the manufacturer’s instructions. Briefly, cDNA template
was prepared from 2.5 μg of total RNA using the high
capacity cDNA archive kit (Life Technologies). The sam-
ples were next subjected to real time-PCR analysis using
TaqMan mRNA primers and probes on the TaqMan
OpenArray platform. Ct (crossing threshold) values for
each mRNA target was calculated using the OpenArray®
Real-Time qPCR Analysis Software. Expression values
were calculated using the comparative Ct method, with
beta 2 microglogublin (B2M) used as the endogenous
control.
Results
Platelet interactions with ovarian cancer cells are
heterogeneous
59 M and SK-OV-3 cells were incubated with an excess
of platelets under low shear conditions to assess their
ability to adhere to and to activate platelets. The degree
of platelet adhesion or ‘cloaking’ was measured based on
the fluorescent detection of labelled platelets on the sur-
face of cancer cells post incubation, while platelet activa-
tion was measured based on the fluorescent detection of
platelet surface P-selectin. The percentage of SK-OV-3
cells cloaked with platelets was significantly greater com-
pared to 59 M cells (Fig. 1a. 53 % versus 45 %, p =
0.0333). SK-OV-3 cells also induced a higher degree of
platelet activation compared to 59 M cells (64 % versus
50 %, Fig. 1b).
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Platelets induce an EMT-like morphology and gene
expression profile in ovarian cancer cells
We have previously demonstrated that the interaction
between ovarian cancer cells and platelets affected EMT-
related genes [24], a pivotal process in the metastatic
cascade. To further these observations, we investigated
whether EMT-like changes were induced by platelets in
both the SK-OV-3 and 59 M cell lines, and assessed if
the levels of induction correspond to the levels of
platelet-tumour cell interactions. SK-OV-3 and 59 M
cells were co-cultured with platelets for 24 h prior to
analysis. Morphological alterations, including loss of
cell-cell contact and elongation of shape, indicative of a
more mesenchymal like phenotype were observed with
both cell lines when co-cultured with platelets for 24 h
(Fig. 2a). Gene expression analysis of a panel of 11 well
characterised EMT-associated genes was performed by
RT-PCR, significant differences were defined as fold
change ≥ ±2 and p-value ≤ 0.05. In both cell lines, there
was a significant increase in expression of the mesenchy-
mal markers, vimentin (VIM) and plasminogen activator
inhibitor-1 (PAI-1; Serpine1), while there was a signifi-
cant decrease in the expression of the epithelial marker
E-cadherin (CDH1) (Fig. 2b). Additionally, there was an
increase in expression of the EMT associated transcrip-
tion factor, snail homolog 1 (SNAI1), and signalling
protein, jagged 1 (JAG1) (Fig. 2b) in SK-OV-3 cells. In
contrast, there was an increase in the mesenchymal
marker fibronectin 1 (FN1) with the 59 M cells (Fig. 2b).
In line with the previous adhesion and activation data,
the platelet effect on SK-OV-3 cells is more pronounced
compared to 59 M cells. SK-OV-3 cells appear more re-
sponsive to platelet interactions, both in relation to the
level and number of EMT-like gene expression changes
occurring (Fig. 2b). Overall, these results demonstrate
that in vitro, platelets promote a more mesenchymal-like
phenotype in ovarian cancer cells.
Platelets significantly enhance the metastatic activity of
SK-OV-3 cells
Platelet-induced EMT-like alterations were not only
observed at the transcriptome level but also morpho-
logically. To determine whether these changes were of
functional importance, we next investigated if platelet
cloaked cancer cells had an altered invasive phenotype.
Cell lines were incubated alone and with platelets for
Fig. 1 Platelet interactions with ovarian cancer cells are significantly
heterogeneous. a Platelet adhesion to 59 M (black bar) and SK-OV-3
(white bar) cells was quantified based on the fluorescence detection
of CD42b positive platelets (n = 3). *p = 0.0333 was determined by
Student’s t test. b Platelet activation by 59 M (black bar) and SK-OV-3
(white bar) cells was quantified based on the fluorescence detection
of P-selectin (CD62P) positive platelets (n = 3). Data shown are
mean values + SD
Fig. 2 Platelets induce a mesenchymal-like state in ovarian cancer cells. a Phase-contrast micrographs of 59 M and SK-OV-3 cells grown in the
absence (media) or presence of platelets for 24 h. b Results are expressed as fold change in mRNA expression in 59 M (black bar) or SK-OV-3
(white bar) cells in the presence of platelets relative to control cells grown in the absence of platelets for 24 h (n = 3). Values are normalised to
B2M (beta 2 microglobulin). Data shown are mean value + SD. **p≤ 0.01, *p≤ 0.05 was determined by Student’s t test
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24 h, and then allowed to invade in Matrigel® chambers
for a further 16 and 24 h. Platelets did not increase the
invasive properties of 59 M cells (Fig. 3a). These cells
alone had a very high propensity to invade (range: 43–
47 % invasion) and therefore it was difficult to assess a
direct effect of the addition of platelets on their ability
to invade using the Matrigel® invasion assay. In con-
trast, SK-OV-3 cells had a low invasion activity by
themselves (13 % after both 16 and 24 h). Co-culture
with platelets resulted in a significant increase in SK-
OV-3 cell invasion. Platelets induced a 3.8-fold (p =
0.0001) and 3.5-fold (p < 0.0001) increase in SK-OV-3
cell invasion after 16 and 24 h, respectively (Fig. 3a).
Furthermore, co-culture of SK-OV-3 cells with platelets
resulted in a similar high invasion activity to that of
59 M cells alone (49 % versus 47 % after 16 h, and 46 %
versus 43 % after 24 h, respectively, Fig. 3a). The dra-
matically different invasion rates observed between the
two cancer cell lines is negated when SK-OV-3 cells are
exposed to platelets.
SK-OV-3 cells have a more epithelial-like phenotype
compared to 59 M cells
To identify the molecular mechanism that facilitates
high invasion of 59 M cells compared to SK-OV-3 cells
in the absence of platelets, we further interrogated the
gene expression profile of the 11 selected EMT markers.
These results indicate that while both SK-OV-3 and
59 M cells originate from the ascites of patients with
metastatic ovarian cancer, their molecular phenotypes
are significantly different. SK-OV-3 cells appear to have
a more epithelial-like phenotype compared to 59 M
cells. This is indicated by the higher expression levels of
the epithelial associated markers E-cadherin (CDH1)
and epithelial cell adhesion molecule (EpCAM); and
lower levels of the mesenchymal markers fibronectin 1
(FN1), claudin (CLDN1) and neural cell adhesion mol-
ecule 1 (NCAM1) (Fig. 3b). There are some exceptions
to this characterisation with the mesenchymal markers
snail homology 2 (SNAI2) and jagged 1 (Jag1) observed
to be higher in SK-OV-3 cells. However, the overall pat-
tern of expression, in particular the high expression of
epithelial markers, would indicate that SK-OV-3 cells
have a more epithelial-like phenotype compared to 59 M
cells. This result explains the highly invasive nature of
59 M cells in the absence of platelets.
Antiplatelet agents significantly reduced the invasion-
promoting properties of platelets on SK-OV-3 cells
Having determined that platelets enhance invasion of
SK-OV-3 cells, we next investigated if antiplatelet agents
effected this interaction. We examined the effect of two
widely used antiplatelet therapies: P2Y12 inhibition and
COX-1 inhibition. Each donor had a RI of ≥70 % in re-
sponse to each antiplatelet agent, as determined by light
transmission aggregometry, and therefore was defined as
aspirin- and 2MeSAMP-responders (data not shown).
2MeSAMP inhibits platelet function by increasing the
levels of cyclic AMP and/or actively competing with
Fig. 3 Platelets significantly increase SK-OV-3 cell invasion activity. a Results are expressed as the percentage of 59 M (black bar) and SK-OV-3
(white bar) cell invasion, in the absence and presence of platelets (plts), through Matrigel® invasion chambers relative to control chambers after
16 and 24 h (n = 6). b SK-OV-3 cells overall have a higher expression level of epithelial markers and lower expression level of mesenchymal
markers compared to 59 M. Results are expressed as fold change values that represent the difference in the baseline mRNA expression level of
epithelial and mesenchymal markers in SK-OV-3 cells compared to their baseline mRNA expression in 59 M cells (n = 3). Values were normalised to beta
2 microglogublin (B2M). Data shown are mean value + SD. ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 was determined by Student’s t test
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ADP for the P2Y12 receptor [30]. Upon addition of
platelets pre-treated with 50 μM 2MeSAMP, the inva-
sion activity of SK-OV-3 cells significantly decreased
4.3- and 2.5-fold compared to those incubated with
untreated platelets after 16 and 24 h respectively (p =
0.0065 and p = 0.0118, Fig. 4a). Prevention of ADP-
induced platelet activation using 2MeSAMP effectively
reverted platelet cloaked SK-OV-3 cell invasion to
levels comparable to SK-OV-3 cells alone (11 % versus
13 %, and 14 % versus 17 %, after 16 h and 24 h, re-
spectively). No significant changes in SK-OV-3 cell
invasion activity were observed when cells were pre-
treated with 2MeSAMP alone. Next we studied the
effect of aspirin which irreversibly disrupts platelet
function by inhibiting the COX-1 enzyme. Exposure of
SK-OV-3 cells to platelets pre-treated with 20 μM as-
pirin resulted in a 2- and 1.6-fold significant reduction
in their invasion activity compared to those incubated
with untreated platelets after 16 and 24 h respectively
(p = 0.012 and p = 0.0214, respectively, Fig. 4b). In con-
trast to P2Y12 inhibition, although COX-1 inhibition
did significantly decrease the platelet-mediated stimula-
tory effect on the invasion activity of SK-OV-3 cells, it
did not completely abolish the platelet effect. When
compared with SK-OV-3 cells alone, those exposed to
platelets pre-treated with aspirin had a significantly
increased invasion activity after both 16 and 24 h (13 %
versus 23 %; and 13 % versus 28 %, p = 0.028, respectively).
Platelet adhesion and platelet-induced EMT gene
expression alterations are not inhibited by antiplatelet
agents
We next sought to determine whether antiplatelet agents
could inhibit platelets from cloaking and inducing EMT-
like molecular changes in SK-OV-3 cells. The degree of
platelet cloaking was measured based on the fluorescent
detection of labelled platelets on the surface of cancer
cells post incubation. The ability of platelets to adhere to
SK-OV-3 cells was not diminished in the presence of
either aspirin or 2MeSAMP (Fig. 5a). xFurthermore,
analysis of the gene expression profile of the 11 selected
EMT markers in SK-OV-3 cells incubated with drug
treated and untreated platelets for 24 h were preformed.
While pre-treatment of platelets with antiplatelet agents
diminishes the platelet-induced invasion capacity of SK-
OV-3 cells, it did not inhibit their ability to induce gene
expression alterations in EMT-related genes. There were
no significant differences in the expression values be-
tween SK-OV-3 cells exposed to platelets and those
exposed to platelets pre-treated with either antiplatelet
agent (Fig. 5b and c).
Discussion
At initial diagnosis, patients with ovarian cancer often
present with widespread metastasis, and this tumour
burden constitutes a major clinical management chal-
lenge. The biological mechanism driving this route of
Fig. 4 Antiplatelet agents significantly reduce platelet-mediated SK-OV-3 cell invasion. Results are expressed as the percentage of SK-OV-3 cell
invasion, in the absence and presence of (a) 2MeSAMP-treated platelets (plts) and (b) aspirin-treated platelets, through Matrigel® invasion
chambers relative to control chambers after 16 and 24 h (n = 4). Data shown are mean value + SD. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05 was
determined by Student’s t test
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metastasis remains poorly understood. Platelet interactions
with CTCs play a key role in successful haematogenous
metastasis. We investigated the interactions between plate-
lets and two metastatic ovarian cancer cells lines, and
found them to be significantly heterogeneous. In compari-
son to 59 M cells, SK-OV-3 cells induced significantly
higher levels of both platelet adhesion and activation, two
key events in TCIPA. Previous studies have found that
there is a direct correlation between the ability of CTCs to
interact with platelets via TCIPA, and their increased sur-
vival in circulation and subsequent formation of metastatic
foci [31, 32]. The ability of SK-OV-3 cells to induce high
Fig. 5 Antiplatelet agents do not affect the ability of platelets to bind to or to induce EMT-like changes in SK-OV-3 cells. a Platelet adhesion
to SK-OV-3 cells in the presence and absence of aspirin or 2MeSAMP was quantified based on the fluorescence detection of CD42b positive
platelets (n = 5). b Results are expressed as fold change in mRNA expression in SK-OV-3 cells in the presence of platelets (black bar) and
platelets pre-treated with 2MeSAMP (white bar) relative to cells grown in the absence of platelets for 24 h (n = 3). c Results are expressed as
fold change in mRNA expression in SK-OV-3 cells in the presence of platelets (black bar) and platelets pre-treated with aspirin (white bar)
relative to cells grown in the absence of platelets for 24 h (n = 3). Values are normalised to B2M (beta 2 microglobulin). Data shown are mean
value + SD. Student’s t-test was performed to determine significant differences between expression levels of the EMT markers in the SK-OV-3
cells cultured with platelets compared with those cultured with platelets pre-treated with antiplatelet agents. No significant differences were
identified (significance was defined as p ≤ 0.05)
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levels of TCIPA suggests these cells may have a depend-
ency on platelets for initiation and/or enhancement of
metastasis.
Although each cell line induced different levels of
TCIPA, we found that the direct interaction between
platelets and both cancer cells induced similar EMT-like
morphological changes. Interestingly, while both cell
lines displayed changes from a characteristic epithelial-
like morphology to a more spindle, fibroblast-like shape
with migratory protrusions, there were distinct differ-
ences in their expression profiles. Platelets significantly
increased upregulation of JAG1 and SNAI1 in SK-OV-3
cells. JAG1, which encodes a ligand for the Notch recep-
tor, has been shown to induce expression of SNAI2,
which along with SNAI1, form part of a key network of
transcription factors identified to regulate epithelial-to-
mesenchymal plasticity through repression of E-cadherin
[33, 34]. Upregulation of these two key mediators of
EMT were not observed in the expression profile of
59 M cells cloaked with platelets. During EMT cancer
cells have been reported to go through an intermediate
phase, where both epithelial and mesenchymal charac-
teristics are present [35, 36]. More recently, SK-OV-3
cells have been described as having an intermediate
mesenchymal state because at the protein level these
cells are E-cadherin negative and pan-cytokeratin and
vimentin positive [37]. Therefore, having observed in-
creased levels of both TCIPA and EMT-like molecular
changes in SK-OV-3 cells, compared to 59 M cells, it is
reasonable to conclude that SK-OV-3 cells are reliant
on platelets to augment their ability to develop a more
favourable mesenchymal-like state to maximise their
ability metastatic capacity.
Indeed, further to these findings we demonstrated
that platelets had a significantly stimulatory effect on
the invasive capacity of SK-OV-3 cells. Co-incubation
of SK-OV-3 cells and platelets appeared to induce a
more aggressive phenotype in these cells. Platelets in-
duced over a 3-fold increase in SK-OV-3 cell invasion
at a ratio of 1 cancer cell to 1000 platelets. This ratio is
approximately 10–100 times lower than physiological
concentrations, suggesting that levels of platelets that
promote invasion are present in vivo. In contrast, 59 M
cells had an intrinsic ability to invade in the absence of
platelets. Their interaction with platelets did not augment
their invasive capabilities. In fact, platelets appeared to
have little stimulatory effect on 59 M cells despite our
previous findings that they induce an EMT-like state in
these cells. This suggests that platelet interactions with
ovarian cancer cells are heterogeneous, both in terms of
adhesion and alterations in phenotypic behaviour. The ob-
served difference is most likely due to the finding that SK-
OV-3 cells are more epithelial-like at the outset than
59 M cells. Thus, when SK-OV-3 cells come in contact
with platelets the effect of transitioning to a more
mesenchymal-like state has a more dramatic effect on
their overall invasive phenotype. These results support
previous findings that cancer cells that have intravasated
into the bloodstream without losing their epithelial-like
characteristics can acquired a mesenchymal-like pheno-
type in transit via interaction with platelets [15].
Recently published secondary analyses of cardiovascu-
lar trials indicate that daily aspirin reduces not only the
short- and long-term risk of death due to cancer, but
also distant metastasis by up to 50 % [25–27]. Although
multiple mechanisms affecting enzyme activity, tran-
scription factors, cellular signalling and mitochondrial
functions have been proposed [38], the chemopreventa-
tive effects of aspirin have not been consistently ob-
served in all studies, and thus it is likely that additional
mechanisms are involved. More recently, reports have
emerged examining the chemopreventative properties of
other antiplatelet agent classes, including those targeting
ADP receptors P2Y2 and P2Y12. Studies have shown that
P2Y2 and P2Y12-deficient mice exhibited decreased
tumour metastasis [39, 40]. Furthermore, the P2Y12 in-
hibitor ticagrelor was shown to significantly decrease
metastasis and improve overall survival in a melanoma
mouse model [41]. The finding that platelets increased
the ability of SK-OV-3 cells to invade led us to investi-
gate whether this effect could be reversed by pre-
treating platelets with antiplatelet agents. During TCIPA,
activated platelets secrete several potent factors, includ-
ing thromboxane A2 and ADP, activated via the COX-1
and P2Y12 platelet activation pathways respectively,
which in turn heightens the process of activation and ag-
gregation. Our results show that inhibiting these path-
ways leads to a significant abrogation of invasiveness of
SK-OV-3 cells. This effect was particularly evident after
exposure of SK-OV-3 cells to platelets that were pre-
treated with 2MeSAMP. Prevention of ADP-induced
platelet activation using 2MeSAMP effectively reversed
invasion to levels comparable to SK-OV-3 cells alone.
While a significant decrease in invasion was observed
upon exposure to aspirin, levels were still significantly
higher compared to SK-OV-3 cells alone. These results
suggest that the P2Y12 inhibitor 2MeSAMP has a greater
inhibitory effect on the ability of SK-OV-3 cells to invade
in the bloodstream compared to aspirin.
Upon further molecular interrogation of SK-OV-3 cells
exposed to platelets pre-treated with either aspirin or
2MeSAMP, we found that their EMT profile was not al-
tered. These results suggest that neither drug plays a dir-
ect role in the regulation of epithelial-to-mesenchymal
plasticity, and therefore another mechanism by which
they exert their cancer-protective effect is likely. During
cancer progression, TCIPA leads to the release of nu-
merous soluble growth factors from alpha granules of
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activated platelets, which may also prime cancer cells for
invasion. For example, the release of PDGF (platelet-de-
rived growth factor), VEGF (vascular endothelial growth
factor), uPA (urokinase plasminogen activator) and
TGF-β have all been shown to increase the invasive cap-
abilities of cancer cells in vitro [15, 42, 43]. Additionally,
matrix metalloproteinase (MMP) expression is report-
edly increased in the process of TCIPA to facilitate
tumour cell migration and invasion [44–46]. MMPs are
zinc-dependent endopeptidases that are involved in the
degradation of extracellular matrix and are involved in
the structural remodelling process. Numerous studies
demonstrate that aspirin can inhibit the expression and
release of MMP-2 and MMP-9 [47, 48]. Jiang et al. re-
ported that aspirin inhibits MMP-2 activity and in vitro
invasion of liver cancer cells [49]. Similarly, Tasi et al.
demonstrated that aspirin inhibits MMP-2 production
and reduces colorectal metastasis in a mouse model
[50]. SK-OV-3 cells have been previously shown to se-
crete both MMP-2 and MMP-9 [51]. Therefore, it is
possible that the decreased invasion we observed in our
system may be as a direct result of aspirin inhibiting the
release of essential MMPs from platelets which aid in
degrading the extracellular matrix and subsequent
extravasation.
Conclusions
In conclusion, we demonstrate a new mechanism of
platelet-cancer cell interactions. Our results demonstrate
that platelet adhesion to ovarian cancer cells transforms
them into an EMT phenotype, both functionally and at a
molecular level, which is essential for migration, extrava-
sation and formation of distant metastasis. Moreover we
demonstrate for the first time that inhibiting platelet
function using aspirin and 2MeSAMP disrupts the crit-
ical extravasation step in the cascade of metastatic ovar-
ian cancer. As P2Y12 inhibitors are now used routinely
in the clinic, our data suggests that this class of anti-
platelet agent may be a therapeutic option to prevent
tumour metastasis in specific cancers.
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